首页> 外文期刊>Breast Cancer Research and Treatment >High-throughput resequencing in the diagnosis of BRCA1/2 mutations using oligonucleotide resequencing microarrays
【24h】

High-throughput resequencing in the diagnosis of BRCA1/2 mutations using oligonucleotide resequencing microarrays

机译:使用寡核苷酸重测序微阵列的高通量重测序诊断BRCA1 / 2突变

获取原文
获取原文并翻译 | 示例
           

摘要

Breast cancer is the most frequent form of carcinoma in European females (incidence 65 per 100,000). In about 10% of all cases, pedigree analysis predicts a hereditary breast-ovarian cancer syndrome (HBOC) to be causative for the disease. Frequently, mutations in two genes, BRCA1 (Chr. 17q21) and BRCA2 (Chr. 13q12), are associated with HBOC. In females, mutations in these genes result in a lifetime risk of 80–85% for breast cancer and 54% (BRCA1) or 23% (BRCA2) for ovarian cancer. Current genetic diagnostic tools for BRCA1 and BRCA2 remain laborious and expensive. Here, we present the first oligonucleotide resequencing microarray covering the complete coding sequence of both genes. In total, 36 previously characterized DNAs were resequenced; all 11 patients with single-nucleotide mutations and, due to a special mutational design, eight patients with heterozygous deletions were detected correctly. In total, 47 different single-nucleotide variants (SNVs) were found. A newly developed software, SeqC, reduced the number of ambiguous calls with the help of a statistical module comparing the acquired data to an online-database. SeqC improved the average call rate to 99% (GSeq: 97%) and reduced time and efforts for manual analysis. SeqC confirmed the results obtained by GSeq and found an additional 33 sequences changes representing 14 SNVs. In total, 945 kb were screened and the overall turnaround time for each patient took approximately 3 days, including analysis.
机译:乳腺癌是欧洲女性中最常见的癌症形式(每10万人中有65例发生)。系谱分析预测,在所有病例中约有10%可能是遗传性卵巢癌综合症(HBOC)的病因。通常,两个基因BRCA1(Chr。17q21)和BRCA2(Chr。13q12)的突变与HBOC相关。在女性中,这些基因的突变导致乳腺癌的终生风险为80-85%,卵巢癌为54%(BRCA1)或23%(BRCA2)。目前用于BRCA1和BRCA2的基因诊断工具仍然费力且昂贵。在这里,我们介绍了第一个寡核苷酸重测序微阵列,涵盖了两个基因的完整编码序列。总共对36个先前鉴定过的DNA进行了重新测序。所有11例具有单核苷酸突变的患者,由于特殊的突变设计,均正确检测了8例具有杂合缺失的患者。总共发现了47种不同的单核苷酸变体(SNV)。借助统计模块将获取的数据与在线数据库进行比较,新开发的软件SeqC减少了歧义调用的次数。 SeqC将平均呼叫率提高到99%(GSeq:97%),并减少了手动分析的时间和精力。 SeqC证实了GSeq获得的结果,并发现了代表14个SNV的另外33个序列变化。总共筛选了945 kb,包括分析在内,每位患者的总处理时间约为3天。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号